|
|
Дата |
|---|
| 20:53 |
| 13.11.2026 |
| 12.11.2026 |
| 11.11.2026 |
| 10.11.2026 |
| 09.11.2026 |
| 06.11.2026 |
| 05.11.2026 |
| 04.11.2026 |
| 03.11.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
3.28
|
3.40
|
3.47
|
3.30
|
3.47
|
3.38
|
|
|
37 981.34
|
309.00
|
|
3.01
|
3.65
|
3.75
|
3.46
|
3.95
|
3.47
|
|
|
71 368.29
|
255.00
|
|
3.50
|
3.84
|
3.8979
|
3.623
|
3.92
|
3.73
|
|
|
95 011.78
|
538.00
|
|
3.88
|
5.38
|
4.055
|
3.60
|
4.055
|
3.88
|
|
|
124 272.22
|
567.00
|
|
3.86
|
5.48
|
4.47
|
4.01
|
4.75
|
4.02
|
|
|
377 629.86
|
830.00
|
|
4.43
|
5.48
|
4.44
|
4.25
|
4.80
|
4.47
|
|
|
456 208.56
|
713.00
|
|
4.10
|
5.48
|
4.20
|
4.13
|
4.6731
|
4.415
|
|
|
219 386.90
|
370.00
|
|
4.10
|
5.48
|
4.55
|
4.26
|
4.83
|
4.34
|
|
|
416 178.93
|
711.00
|
|
4.10
|
5.48
|
4.80
|
4.53
|
4.90
|
4.565
|
|
|
353 329.19
|
491.00
|
|
4.73
|
5.48
|
4.69
|
4.69
|
4.90
|
4.77
|
|
|
135 427.80
|
276.00
|
LeonaBio, Inc., formerly Athira Pharma, Inc., is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The Company's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease.
Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations.
Показать все Скрыть